|
1
|
Gerstberger S, Jiang Q and Ganesh K:
Metastasis. Cell. 186:1564–1579. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guckenberger M, Lievens Y, Bouma AB,
Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B,
Hurkmans C, Lecouvet FE, et al: Characterisation and classification
of oligometastatic disease: A European society for radiotherapy and
oncology and european organisation for research and treatment of
cancer consensus recommendation. Lancet Oncol. 21:e18–e28. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haslam A and Prasad V: Estimation of the
percentage of US patients with cancer who are eligible for and
respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw
Open. 2:e1925352019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hellman S and Weichselbaum RR:
Oligometastases. J Clin Oncol. 13:8–10. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salama JK and Milano MT: Radical
irradiation of extracranial oligometastases. J Clin Oncol.
32:2902–2912. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gomez DR, Tang C, Zhang J, Blumenschein GR
Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, et
al: Local consolidative therapy vs maintenance therapy or
observation for patients with oligometastatic non-small-cell lung
cancer: Long-term results of a multi-institutional, phase II,
randomized study. J Clin Oncol. 37:1558–1565. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Palma DA, Olson R, Harrow S, Gaede S,
Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP,
et al: Stereotactic ablative radiotherapy for the comprehensive
treatment of oligometastatic cancers: Long-term results of the
SABR-COMET phase II randomized trial. J Clin Oncol. 38:2830–2838.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kao J, Farrugia MK, Frontario S, Zucker A,
Copel E, Loscalzo J, Sangal A, Darakchiev B, Singh A and Missios S:
Association of radiation dose intensity with overall survival in
patients with distant metastases. Cancer Med. 10:7934–7942. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kao J, Gold KD, Zarrili G, Copel E,
Silverman AJ, Ramsaran SS, Yens D and Ryu S: Clinical predictors of
survival for patients with stage IV cancer referred to radiation
oncology. PLoS One. 10:e01243292015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zucker A, Tsai CJ, Loscalzo J, Calves P
and Kao J: The NEAT predictive model for survival in patients with
advanced cancer. Cancer Res Treat. 50:1433–1443. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Willmann J, Vlaskou Badra E, Adilovic S,
Ahmadsei M, Christ SM, van Timmeren JE, Kroeze SGC, Mayinger M,
Guckenberger M and Andratschke N: Evaluation of the prognostic
value of the ESTRO EORTC classification of oligometastatic disease
in patients treated with stereotactic body radiotherapy: A
retrospective single center study. Radiother Oncol. 168:256–264.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baker S, Mou B, Jiang W, Liu M, Bergman
AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T,
et al: Validation of the prognostic utility of ESTRO/EORTC
oligometastatic disease classification: A secondary analysis from
the population-based phase II SABR-5 trial. Int J Radiat Oncol Biol
Phys. 114:849–855. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chalkidou A, Macmillan T, Grzeda MT,
Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry
L, et al: Stereotactic ablative body radiotherapy in patients with
oligometastatic cancers: A prospective, registry-based, single-arm,
observational, evaluation study. Lancet Oncol. 22:98–106. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Vin T, Engels B, Gevaert T, Storme G
and De Ridder M: Stereotactic radiotherapy for oligometastatic
cancer: A prognostic model for survival. Ann Oncol. 25:467–471.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong JC, Ayala-Peacock DN, Lee J,
Blackstock AW, Okunieff P, Sung MW, Weichselbaum RR, Kao J, Urbanic
JJ, Milano MT, et al: Classification for long-term survival in
oligometastatic patients treated with ablative radiotherapy: A
multi-institutional pooled analysis. PLoS One. 13:e01951492018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Poon I, Erler D, Dagan R, Redmond KJ,
Foote M, Badellino S, Biswas T, Louie AV, Lee Y, Atenafu EG, et al:
Evaluation of definitive stereotactic body radiotherapy and
outcomes in adults with extracranial oligometastasis. JAMA Netw
Open. 3:e20263122020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sutera P, Clump DA, Kalash R, D'Ambrosio
D, Mihai A, Wang H, Petro DP, Burton SA and Heron DE: Initial
results of a multicenter phase 2 trial of stereotactic ablative
radiation therapy for oligometastatic cancer. Int J Radiat Oncol
Biol Phys. 103:116–122. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chmura S, Winter KA, Robinson C, Pisansky
TM, Borges V, Al-Hallaq H, Matuszak M, Park SS, Yi S, Hasan Y, et
al: Evaluation of safety of stereotactic body radiotherapy for the
treatment of patients with multiple metastases: Findings from the
NRG-BR001 phase 1 trial. JAMA Oncol. 7:845–852. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Greto D, Scoccianti S, Compagnucci A,
Arilli C, Casati M, Francolini G, Cecchini S, Loi M, Desideri I,
Bordi L, et al: Gamma knife radiosurgery in the management of
single and multiple brain metastases. Clin Neurol Neurosurg.
141:43–47. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsai CJ: Moving away from counting the
numbers: Leveraging a sensible clinical trial design for
oligometastatic disease and beyond. Int J Radiat Oncol Biol Phys.
114:846–848. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gupta D and Lis CG: Pretreatment serum
albumin as a predictor of cancer survival: A systematic review of
the epidemiological literature. Nutr J. 9:692010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iyengar P: Local therapy for
oligometastatic disease-cart before the horse? Int J Radiat Oncol
Biol Phys. 114:836–839. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chavez-MacGregor M, Lei X, Zhao H, Scheet
P and Giordano SH: Evaluation of COVID-19 mortality and adverse
outcomes in US patients with or without cancer. JAMA Oncol.
8:69–78. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lamont EB, Hayreh D, Pickett KE, Dignam
JJ, List MA, Stenson KM, Haraf DJ, Brockstein BE, Sellergren SA and
Vokes EE: Is patient travel distance associated with survival on
phase II clinical trials in oncology? J Natl Cancer Inst.
95:1370–1375. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ledesma Vicioso N, Lin D, Gomez DR, Yang
JT, Lee NY, Rimner A, Yamada Y, Zelefsky MJ, Kalman NS, Rutter CE,
et al: Implementation strategies to increase clinical trial
enrollment in a community-academic partnership and impact on
hispanic representation: An interrupted time series analysis. JCO
Oncol Pract. 18:e780–e785. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sanz-Garcia E, Zhao E, Bratman SV and Siu
LL: Monitoring and adapting cancer treatment using circulating
tumor DNA kinetics: Current research, opportunities, and
challenges. Sci Adv. 8:eabi86182022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gallicchio L, Devasia TP, Tonorezos E,
Mollica MA and Mariotto A: Estimation of the number of individuals
living with metastatic cancer in the United States. J Natl Cancer
Inst. 114:1476–1483. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Langbaum T and Smith TJ: Time to study
metastatic-cancer survivorship. N Engl J Med. 380:1300–1302. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baker S, Mou B, Jiang W, Liu M, Bergman
AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T,
et al: Predictors of early polymetastatic relapse after SABR for up
to 5 oligometastases: A secondary analysis of the phase II SABR-5
trial. Int J Radiat Oncol Biol Phys. 114:856–861. 2022. View Article : Google Scholar : PubMed/NCBI
|
